December 12, 2013 | BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, has announced that it was awarded an $800,000 non-dilutive grant from Israel’s Office of the Chief Scientist (OCS) for the year 2014. The grant is intended to support BrainStorm’s clinical and product development for its stem cell therapy candidate NurOwn.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments